AIM ImmunoTech filed an SEC prospectus for the resale of up to 13,077,089 common stock shares.
Selling stockholders will offer these shares, meaning the company is not raising new capital for operations.
The shares were originally issued during a direct offering and private placement that closed on June 10, 2026.
This resale prospectus allows early private placement investors to sell their holdings on the open market.
An increased public supply of shares may create downward pressure on the company's stock price.